Currently, most therapeutic antibody discovery strategies start by binder screening, followed by purification of these antibodies for further functional characterization. However, massive resources are invested into the time-consuming step-by-step screening schema, and arbitrary selection of candidates purely based on binding capability further compromises diversity.
In this technical manual, there will be solutions that can be applied to current antibody discovery platforms to overcome this issue and significantly improve process efficiency.
Attachment(s)
BioMelbourne NetworkLevel 6, HWT Tower40 City RoadSouthbank, VIC 3006